so title is technically in his name for leronlimab
Post# of 148176
my point is a few want to replace him when he is the actual owner of the
leronlimab patent.may not work out so well for shareholders?perhaps the respectful way to deal with the situation is a suggestion that he gets a very skilled exec to help him?imo